SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Philip Bonomi, M.D., Rush University Medical Center, Chicago
Philip Bonomi has been a clinical investigatore in lung cancer, with primary focus in non-small cell lung cancer for three decades.He was involved in the development of carboplatin, paclitaxel, and erlotinib in addvanced non-small cell lung cancer in early combined modality studies evaluating simultaneous chemoradiation as neoadjuvant treatment. Most recently he has been working with targeted therapies and molecular profiles which might have prognostic or predictive value in lung cancer.
Karen Kelly, M.D., University of Kansas Medical Center, Kansas City, Kan.
Karen Kelly, MD, is Deputy Director, Associate Director of Clinical Research, and the Frank B. Tyler Professor at The University of Kansas Cancer Center and School of Medicine in Kansas City.
After earning her medical degree at The University of Kansas School of Medicine, Dr Kelly completed her residency and her oncology fellowship at the University of Colorado Health Sciences Center. She built an academic career in thoracic oncology at the University of Colorado, where she was a faculty member for 16 years before leaving to accept her current position.
As Principal and Co-Principal Investigator, Dr Kelly has participated in the development of numerous clinical trials evaluating anticancer agents, primarily for small cell and nonƒ{small cell lung cancer. She has authored and coauthored nearly 100 publications, including original papers, abstracts, books, and book chapters. The results of her extensive research in lung cancer have appeared in several prominent oncology journals such as, the Journal of Clinical Oncology, Clinical Cancer Research, and Lung Cancer.
Dr Kelly is an active member of many professional organizations, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. In addition, she serves as Vice Chair of the Southwest Oncology Group Lung Committee.